Pulmonx Corp.
Regulated industryPhysical productsSells to businessesTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $2.74
- 52-Week Range
- $1.13 – $3.25
- Market Cap
- $117.15M
- P/E (TTM)
- —
- EPS (TTM)
- -1.01
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 3.43
- PEG Ratio
- —
- Return on Equity
- -90.31%
- Return on Assets
- -19.82%
- Gross Margin
- 77.42%
- Operating Margin
- -44.39%
- Profit Margin
- -47.93%
- Current Ratio
- 4.05
- Debt/Equity
- 1.65
- Total Debt
- $56.35M
- Free Cash Flow
- $-9.47M
- Revenue Growth
- 6.20%
- Earnings Growth
- —
- Enterprise Value
- $120.81M
Market Snapshot
About
Pulmonx Corp. is a commercial-stage medical technology company focused on minimally invasive treatments for chronic obstructive pulmonary disease (COPD) and emphysema. The company developed the Zephyr Endobronchial Valve, a small one-way valve implanted in the airways to help severe emphysema patients breathe more easily. Their products are designed to reduce lung hyperinflation without surgery.